威尔药业(603351) - 2022 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2022 was CNY 290,586,279.28, representing a year-on-year increase of 27.77%[4] - The net profit attributable to shareholders for the same period was CNY 27,529,731.11, reflecting a growth of 5.04% compared to the previous year[4] - Total operating revenue for Q1 2022 was CNY 290,586,279.28, an increase of 27.8% compared to CNY 227,430,578.90 in Q1 2021[16] - Net profit for Q1 2022 was CNY 26,763,211.11, slightly up from CNY 26,209,240.14 in Q1 2021, reflecting a growth of 2.1%[17] - The net profit attributable to the parent company for Q1 2022 was CNY 27,529,731.11, an increase from CNY 26,209,240.14 in Q1 2021, representing a growth of approximately 5%[18] - The company reported a total comprehensive income of CNY 26,763,211.11 for Q1 2022, compared to CNY 26,209,240.14 in Q1 2021, indicating a growth of approximately 2.1%[18] Earnings and Shareholder Returns - The basic earnings per share for Q1 2022 was CNY 0.21, up by 5.00% year-on-year[4] - The basic and diluted earnings per share for Q1 2022 were both CNY 0.21, compared to CNY 0.20 in the same period last year, indicating a 5% increase[19] Assets and Liabilities - The total assets at the end of the reporting period amounted to CNY 1,948,551,368.50, which is a 5.82% increase from the end of the previous year[5] - Total assets reached CNY 1,948,551,368.50 as of March 31, 2022, up from CNY 1,841,426,562.78 at the end of 2021, indicating a growth of 5.8%[14] - Total liabilities increased to CNY 526,057,783.36 from CNY 456,012,175.77, reflecting a rise of 15.3%[14] Cash Flow - Cash flow from operating activities showed a net increase of 134.47% due to higher sales revenue[7] - Cash inflow from operating activities for Q1 2022 was CNY 214,485,323.46, up from CNY 139,927,816.64 in Q1 2021, marking a growth of about 53%[19] - The net cash flow from operating activities for Q1 2022 was CNY 9,037,458.54, a significant improvement from a net outflow of CNY 26,216,473.71 in Q1 2021[19] - Cash inflow from financing activities in Q1 2022 was CNY 115,370,000.00, compared to CNY 61,688,970.93 in Q1 2021, reflecting an increase of approximately 87%[20] - The net cash flow from financing activities for Q1 2022 was CNY 66,972,377.01, up from CNY 53,605,980.77 in Q1 2021, showing an increase of about 25%[20] - The total cash and cash equivalents at the end of Q1 2022 amounted to CNY 133,470,273.95, down from CNY 150,064,013.89 at the end of Q1 2021[20] Investment Activities - The company reported a net cash outflow from investing activities of -118.68%, primarily due to reduced project payments[7] - The cash outflow from investing activities for Q1 2022 was CNY 37,367,093.75, compared to CNY 133,876,080.15 in Q1 2021, showing a decrease of about 72%[20] - The company received CNY 28,581,278.02 from investment activities in Q1 2022, a decrease from CNY 180,910,415.47 in Q1 2021, reflecting a decline of approximately 84%[20] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 10,417[9] Research and Development - Research and development expenses for Q1 2022 were CNY 10,847,878.76, compared to CNY 9,498,113.15 in Q1 2021, showing a growth of 14.2%[17] Financial Expenses - The company reported a decrease in financial expenses, which were CNY 2,418,434.28 in Q1 2022, down from CNY 929,220.95 in Q1 2021[17] Inventory and Receivables - Inventory as of March 31, 2022, was CNY 161,128,048.87, an increase of 13.1% from CNY 142,442,042.74 at the end of 2021[12] - The accounts receivable financing decreased by 70.38%, attributed to bank acceptance discounts and endorsements[7] - Short-term borrowings rose to CNY 252,329,771.89 from CNY 171,193,229.29, marking a 47.5% increase[13] - The company's short-term borrowings increased by 47.39% during the reporting period[7]